Table 1.

Comparison of 2008-2009 and 2017-2018 fiscal years of CP patient characteristics in British Columbia

CHARACTERISTICFISCAL YEAR
2008-2009, N=852,8952017-2018, N=946,641
Age, y, n (%)
• 0-1958,045 (6.8)55,267 (5.8)
• 20-39186,248 (21.8)180,198 (19.0)
• 40-59324,003 (38.0)325,821 (34.4)
• 60-79221,911 (26.0)308,086 (32.5)
• ≥8062,688 (7.4)77,269 (8.2)
Administrative sex, n (%)*
• Female523,709 (61.4)573,164 (60.5)
• Male329,108 (38.6)373,472-373,477 (39.5)
• Unknown78 (0.0)≤5
Neighbourhood income quintile, n (%)
• 1 (lowest)176,486 (20.7)188,872 (20.0)
• 2173,657 (20.4)191,832 (20.3)
• 3169,587 (19.9)189,638 (20.0)
• 4164,065 (19.2)189,745 (20.0)
• 5 (highest)157,837 (18.5)177,159 (18.7)
Health authority, n (%)§
• Interior153,787 (18.0)165,098 (17.4)
• Fraser302,514 (35.5)355,162 (37.5)
• Vancouver coastal188,126 (22.1)201,213 (21.3)
• Island153,225 (18.0)170,844 (18.0)
• Northern53,768 (6.3)53,979 (5.7)
Chronic opioid therapy, n (%)39,217 (4.6)49,035 (5.2)
Long-term neuropathic pain medications, n (%)71,876 (8.4)100,845 (10.7)
Long-term NSAIDs, n (%)40,260 (4.7)31,956 (3.4)
Cancer diagnosis, n (%)34,318 (4.0)47,335 (5.0)
No. of outpatient FP visits, mean (SD)9.33 (7.86)8.35 (7.37)
No. of FPs seen as outpatient, mean (SD)2.73 (1.95)2.42 (1.68)
  • CP—chronic pain, NSAID—nonsteroidal anti-inflammatory drug.

  • * Based on consolidation file, does not represent gender or sex assigned at birth.16

  • Number too small to report. Range reported for male sex to mask small value.

  • A total of 11,263 patients in 2008-2009 and 9395 in 2017-2018 had missing neighbourhood income quintiles.

  • § Overall, 1475 patients in 2008-2009 and 345 in 2017-2018 had missing health authorities.

  • Not including basal cell and squamous cell carcinoma.

  • Chronic pain patients may see more than 1 FP per fiscal year.